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Abstract
Background: Evaluation of microbicides for prevention of HIV-1 infection in macaque models for
vaginal infection has indicated that the concentrations of active compounds needed for protection
by far exceed levels sufficient for complete inhibition of infection in vitro. These experiments were
done in the absence of seminal plasma (SP), a vehicle for sexual transmission of the virus. To gain
insight into the possible effect of SP on the performance of selected microbicides, their anti-HIV-1
activity in the presence, and absence of SP, was determined.
Methods: The inhibitory activity of compounds against the X4 virus, HIV-1 IIIB, and the R5 virus,
HIV-1 BaL was determined using TZM-bl indicator cells and quantitated by measuring β-
galactosidase induced by infection. The virucidal properties of cellulose acetate 1,2-benzene-
dicarboxylate (CAP), the only microbicide provided in water insoluble, micronized form, in the
presence of SP was measured.
Results: The HIV-1 inhibitory activity of the polymeric microbicides, poly(naphthalene sulfonate),
cellulose sulfate, carrageenan, CAP (in soluble form) and polystyrene sulfonate, respectively, was
considerably (range ≈ 4 to ≈ 73-fold) diminished in the presence of SP (33.3%). Formulations of
micronized CAP, providing an acidic buffering system even in the presence of an SP volume excess,
effectively inactivated HIV-1 infectivity.
Conclusion: The data presented here suggest that the in vivo efficacy of polymeric microbicides,
acting as HIV-1 entry inhibitors, might become at least partly compromised by the inevitable
presence of SP. These possible disadvantages could be overcome by combining the respective
polymers with acidic pH buffering systems (built-in for formulations of micronized CAP) or with
other anti-HIV-1 compounds, the activity of which is not affected by SP, e.g. reverse transcriptase
and zinc finger inhibitors.
Background
Sexual virus transmission plays the major role in the
worldwide HIV-1 epidemic [1]. In the absence of effective
anti-HIV-1 vaccines, great emphasis has been put on the
development of topical microbicides to be applied vagi-
nally in the form of gels, creams or solid dosage formula-
tions expected to inactivate HIV-1 infectivity or to
interfere with steps in the virus life cycle, preferably block-
ing virus entry into susceptible cells. The model of choice
for evaluating candidate anti-HIV-1 microbicides in vivo
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are female rhesus macaques to whom anti-HIV-1 products
and either simian immunodeficiency virus (SIV) or HIV-
1/SIV hybrid viruses (SHIVs) are consecutively applied in
the vagina [2-7]. Results obtained in this animal model
have indicated that the concentrations of anti-HIV-1 com-
pounds in microbicide formulations adequate to prevent
vaginal infection exceed by several orders of magnitude
concentrations sufficient for complete inhibition of infec-
tion in in vitro systems [8-10]. The macaque model over-
looks the role of human seminal plasma (SP), a common
source of male to female sexual transmission of HIV-1, in
infection and the ultimate effectiveness of microbicides.
Because of impediments for including SP into the
macaque model studies, the effect of this "natural diluent
for HIV-1" on virus inhibitory activity of several candidate
microbicides was investigated. They included the poly-
mers: carrageenan, poly(naphthalene sulfonate) (PRO
2000), cellulose sulfate, cellulose acetate 1,2-benzenedi-
carboxylate (CAP) and polystyrene sulfonate, some of
which are being evaluated in phase III clinical trials for
efficacy [10-12]. Antiretroviral drugs specifically targeted
to HIV-1 reverse transcriptase, UC781 [12,13] and TMC
120 [14,15], respectively, and to the zinc fingers of the
HIV-1 nucleocapsid protein NCp7 [16-18] were included
in control experiments.
Methods
Reagents
Aquateric (the micronized form of CAP containing ≈ 66%
CAP and ≈ 34% of Poloxamer and distilled acetylated
monoglycerides) was obtained from the FMC Biopolymer
Corporation, Philadelphia, PA. The following polymers
were obtained from commercial sources different from
proprietary products being developed as microbicides:
carrageenans κ and λ (Sigma, St. Louis, MO; mixed at a 1:1
(w/w) ratio in all experiments); cellulose sulfate (Across
Organics, Piscataway, NJ); poly(napthalene sulfonate)
(BASF, Parsippany, NJ); and polystyrene-4-sulfonate
(Polysciences, Inc., Warrington, PA).
The HIV-1 non-nucleoside reverse transcriptase inhibi-
tors, UC781 and TMC120 were obtained by custom syn-
thesis from Albany Molecular Research, Inc., Albany, NY.
Zinc finger inhibitors #89 and #247 were a gift from Dr.
Ettore Appella and Dr. Marco Schito (National Cancer
Institute, Bethesda, MD). Stabilite SD60 Polyglycitol,
hydroxypropyl methylcellulose E4M and Avicel PH 105,
respectively, were from SPI Polyols, New Castle, DE, Dow
Chemical Co., Midland, MI and the FMC Biopolymer
Corporation, Philadelphia, PA. SP was purchased from
Vital Products, Inc., Boynton Beach, FL. HIV-1 IIIB and
BaL were from Advanced Biotechnologies, Inc., Colom-
bia, MD. HeLa-CD4-LTR-β-gal, MAGI-CCR5 and TZM-bl
cells were obtained from the AIDS Reagent and Reference
Reagent Program (operated by McKesson BioServices,
Rockville, MD) and contributed by Drs. M. Emerman, J.
Overbaugh and J. C. Kappes and X. Wu (Tranzyme, Inc.),
respectively. Dulbecco's modified Eagle medium
(DMEM) was from GIBCO Invitrogen Corporation,
Carlsbad, CA. The Galacto-Light Plus chemiluminescence
reporter assay for β-galactosidase was from Applied Bio-
systems, Foster City, CA.
Inhibition of infection by anti-HIV-1 compounds in the 
presence or absence of seminal plasma
Seventy  μl of serially two-fold diluted compounds in
DMEM medium (final concentrations after dilution: 1.25
to 10,000 μg/ml) were mixed with 70 μl of HIV-1 IIIB and
BaL, respectively, and 70 μl of either SP or DMEM
medium. The mixtures were added to TZM-bl indicator
cells (in 96-well plates) which can be infected by both X4
and R5 HIV-1, enabling quantitative analysis of HIV-1
infection using either β-galactosidase (β-gal) or luciferase
as a reporter [19]. After 90 min at 37°C, the virus (and SP)
containing supernatants were removed from the cells. The
cells were washed once with DMEM medium, supple-
mented with the same medium, and incubated for 48 hr
at 37°C. The removal of SP after 90 min was necessary to
avoid problems caused by the cytotoxicity of SP evident
after prolonged incubation [20-22]. Finally, the culture
supernatants were removed and the cells were washed
once with phosphate buffered saline, pH 7.2 (PBS). Sub-
sequently, 50 μl of lysis buffer from the Galacto-Light Plus
kit were added to the wells for 1 hr at 20°C. Aliquots (20
μl) of the cell lysates were transferred into wells of 96-well
microplates and β-gal was quantitated using the Galacto-
Light Plus System chemiluminescence reporter assay in a
MicroLight ML 2250 luminometer (Dynatech Laborato-
ries, Inc. Chantilly, VA). The concentration of viruses was
selected so as to provide a readout of ≤ 70 in the absence
of SP and drug, respectively. The percentage of inhibition
was calculated using the Microsoft Excel computer pro-
gram. ED50 values were calculated using an online compu-
ter program [23]. The inhibitory activity of the
compounds in the absence of SP was measured also at a
lower (1/6) virus dose (readout ≤ 20) to determine
whether or not this would result in higher ED50 values.
This was not the case, confirming that the presence of SP
(causing partial virus inactivation or inhibition) truly
diminishes the inhibitory activity of the polymers under
investigation.
Measurements of HIV-1 infectivity
The following two formulations were tested for virucidal
activity against HIV-1 IIIB and BaL, respectively, in the
presence of SP: (1) Aquateric, 18%; glycerol, 58%; Sta-
bilite SD60, 20%; Hydroxypropyl methylcellulose E4M
1%, Avicel PH 105, 3%; and (2) 18% Aquateric in a uni-
versal placebo gel [24].BMC Infectious Diseases 2006, 6:150 http://www.biomedcentral.com/1471-2334/6/150
Page 3 of 10
(page number not for citation purposes)
Two-fold serial dilutions of HIV-1 IIIB treated with Aqua-
teric formulations, and separated from these polymers by
precipitation with 3% PEG or by centrifugation at 14,000
rpm for 1 h, and control virus (100 μl), respectively, were
added to HeLa-CD4-LTR-β-gal cells which had been
plated a day before infection in 96-well plates at 1 × 104
cells/well in 100 μl of DMEM medium containing 10%
fetal bovine serum (FBS). After incubation at 37°C for 48
h, the culture supernatant fluids were removed and the
cells washed once with PBS. β-gal in the cells was meas-
ured as described above. The infectivity of treated and
control HIV-1 BaL was measured by the same method
except that MAGI-CCR5 cells were used.
Measurement of HIV-1 infectivity in seminal fluid is
impeded by the cytotoxicity of SP [20,21] contributed to
by spermine [22]. Therefore, HIV-1 was separated from SP
ingredients by precipitation with 3% PEG or centrifuga-
tion (14,000 rpm for 1 h) and the infectivity of the resus-
pended pellets was measured. Such cytotoxic effects were
minimized by using for titrations of virus infectivity pel-
lets after precipitation with 3% PEG or after centrifugation
(14,000 rpm for 1 h).
Micromethod for CAP quantitation
CAP in the form of a complex with ruthenium red was
quantitated spectrophotometrically [25].
Results
The HIV-1 inhibitory activity of several polymeric 
candidate microbicides is diminished in the presence of 
seminal plasma
Inhibition of HIV-1 IIIB (a virus utilizing CXCR4 as cellu-
lar coreceptor = X4 virus) and HIV-1 BaL (a virus utilizing
CCR 5 as cellular receptor = R5 virus) [8,26] infection,
respectively, of TZM-bl cells [19] by polymeric candidate
microbicides in the absence or presence of SP (final con-
centration 33.3%) was investigated. The polymers
included: carrageenan, poly(naphthalene sulfonate), cel-
lulose sulfate, cellulose acetate 1,2-benzene dicarboxylate
(CAP) and polystyrene sulfonate. Dose response curves
for inhibition of HIV-1 IIIB infection (Fig. 1) show the
suppressive effect of SP on the virus inhibitory activities of
the polymers. Similar results were obtained for HIV-1 BaL
(data not shown). The results are summarized in Table 1
showing values for 50% inhibition of infection (ED50)
corresponding to the distinct polymers. The ED50 values
are consistently higher for HIV-1 BaL than for HIV-1 IIIB.
This is consistent with lower positive charges on V3 loops
of R5 gp120 envelope glycoproteins as compared with X4
gp120, leading to diminished binding of negatively
charged polymers [27,28]. The presence of SP led to a ≈ 4
to ≈ 73-fold increase of ED50, resulting in ED50 values for
HIV-1 BaL (a representative of more frequently sexually
transmitted R5 viruses [8,26]) > 100 μg/ml. This raises the
question whether or not sufficient concentrations of the
respective inhibitors can be reached in the vaginal envi-
ronment at which cells playing a major role in the virus
replicative cycle (dendritic cells, macrophages and CD4+
T cells) occur [11].
In contrast with the polymeric candidate microbicides,
the anti-HIV-1 activities of reverse transcriptase inhibitors
UC781 and TMC120, and of zinc finger inhibitors #89
and #247, respectively, were not affected by the presence
of SP (data not shown). This will support confidence for
results of efficacy tests for these antiretroviral drugs in ani-
mal model systems for male to female virus transmission.
The presence of SP alone (33.3 to 80%) resulted in 4- to
22-fold, and 2- to 10-fold inhibition of HIV-1 IIIB and BaL
infection, respectively, in different experiments.
Direct HIV-1 inactivation in the presence of seminal 
plasma
Anionic polymeric candidate microbicides are thought to
interfere with HIV-1-cell interactions involving cellular
receptors either directly in productive infection (CD4 and
CXCR4/CCR5) or in cell to cell transfer of virus (DC-SIGN
etc.) [11]. However, some polymers rapidly (≤ 5 min)
inactivate HIV-1. Under these circumstances, there is no
need for the antiviral compounds to reach cells involved
in virus dissemination or infection, the virus being ren-
dered non-infectious before encountering cellular/tissue
surfaces. Among the aforementioned polymers, cellulose
sulfate, polystyrene sulfonate, poly(naphthalene sul-
fonate) (at a concentration of 10 mg/ml; at concentra-
tions ≤ 1 mg/ml the compounds may not be virucidal
[29]), CAP (micronized), as well as the acidifying formu-
lation, BufferGel, inactivate not only X4 viruses but also
the R5 virus, HIV-1 BaL [30]. Poly(naphthalene sulfonate)
and CAP, respectively, rapidly elicit in the virus envelope
the formation of "dead-end" gp41 six-helix bundles ren-
dering the virus irreversibly incapable to fuse with suscep-
tible target cells, a prerequisite for infection [30]. CAP
being the only candidate microbicide provided in a water
insoluble micronized form, and therefore, very unlikely to
penetrate into tissues or cells [31], was selected for further
studies regarding the effect of SP on its virus inactivating
properties.
CAP formulations (expected to contain about 240 to 480
mg CAP per dose for human use) have a good acidic buff-
ering capacity, are non-toxic to vaginal and cervical
explants or reconstituted tissues [32], and provide a pH ≤
5.5 if the volume of SP is ≤ 1.8 ml per 100 mg CAP (Fig.
2). CAP remains water insoluble under these conditions
(Fig. 3) and will remain in the form of particles about 1
micron in diameter. Changes in pH and CAP solubility
during the course of addition of SP to formulated CAP (≈
120 mg/ml) are shown in Fig. 4. It is evident that even atBMC Infectious Diseases 2006, 6:150 http://www.biomedcentral.com/1471-2334/6/150
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an excess of SP over the volume of the formulation used
(3:1), the pH remains < 5.5 and the maximum concentra-
tion of CAP becoming soluble is ≤ 7 μg/ml. This concen-
tration is sufficient for partial inhibition of infection by
the laboratory strain HIV-1 IIIB [33] but insufficient for
inhibition of most other HIV-1 strains [34]. Thus, the pre-
dominant contribution to anti-HIV-1 activity of formu-
lated CAP is expected to be attributable to the insoluble
micronized particles even at an excess of SP. These parti-
cles adsorb both X4 and R5 viruses, elicit 6-helix bundle
formation in their envelope glycoproteins and render the
viruses non-infectious [30]. Both HIV-1 IIIB and BaL are
inactivated within 5 min at 37°C by CAP in micronized
form even in the presence of a volume excess of SP (Table
Table 1: Decreased anti-HIV-1 activity of polymeric candidate microbicides in the presence of human seminal plasma
Polymer HIV-1 IIIB HIV-1 BaL
ED50 μg/ml ED50SP μg/ml ED50SP: ED50 ratio ED50 μg/ml ED50SP μg/ml ED50SP: ED50 ratio
Poly (naphthalene sulfonate) 1.1 17.3 15.7 37.5 141 3.8
Cellulose sulfate 1.6 64.7 40.4 7.1 401 56.5
Carrageenan 1.4 63.4 45.6 6.3 149 23.7
Cellulose acetate 1,2-benzenedi-carboxylate 1.0 72.7 72.7 9.8 141 14.4
Polystyrene sulfonate 2.2 36.1 16.4 12.8 389 30.4
SP = seminal plasma added
Inhibition of HIV-1 IIIB infection by negatively charged polymers in the presence (33.3%; v/v), and absence of seminal plasma,  respectively Figure 1
Inhibition of HIV-1 IIIB infection by negatively charged polymers in the presence (33.3%; v/v), and absence of 
seminal plasma, respectively. TZM-bl indicator cells and β-galactosidase readout were used for quantitative analysis of 
HIV-1 infection.
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2). Similar results were obtained with an Aquateric formu-
lation in a "universal placebo" gel [24] (Fig. 5). Virucidal
activity against HIV-1 BaL was still detectable at relatively
high dilutions of the formulation in SP (resulting in pH ≥
7.0), not expected to occur in vivo. The virucidal activity of
CAP was similar to that observed in the absence of SP (see
Fig. 2 in our earlier publication) [35]. In contrast, acidic
pH alone is much less virucidal than CAP in micronized
form, the half-life for virus infectivity being 6, 10 and
>120 min at pH 3.5, 4.0 and 4.5, respectively [36] and
fails to elicit "dead-end" six-helix bundle formation in
HIV-1 gp41 (data not shown). Thus, combination of a
low pH buffering system with a compound targeted to
functionally important sites on HIV-1 envelope glycopro-
teins (e.g. CD4 and/or CXCR4/CCR5 coreceptor binding
sites, and gp41 regions involved in 6-helix bundle forma-
tion) provides an attractive approach for development of
virucidal microbicides. In the case of CAP, the low-pH
buffering capacity is an inherent property of the polymer.
Discussion
Results presented here indicate that SP caused a decrease
in the HIV-1 inhibitory activity of all polymers being con-
sidered as candidate microbicides while inhibition of
virus infection caused by reverse transcriptase and zinc
finger inhibitors remained unaffected. Semen contains
the polyamines spermine, spermidine and putrescine
[37,38] which are positively charged at neutral pH while
the polymeric anti-HIV-1 inhibitors all have negative
charges. Thus, complex formation between the
polyamines and the anti-HIV-1 polymers seems likely.
This is supported by the observed complex formation
pH changes caused by addition of seminal plasma to 180 mg Aquateric Figure 2
pH changes caused by addition of seminal plasma to 180 mg Aquateric. Increasing volumes of seminal plasma were 
added to 180 mg Aquateric, and pH was measured. Aquateric is a micronized form of CAP and consists of ≈ 67% CAP and ≈ 
33% poloxamer + distilled acetylated monoglycerides. CAP formulations have been designed to contain 180 mg Aquateric per 
gram of formulation.
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between polyamines and sulfonic and carboxylic poly-
anions [39,40]. In agreement with this, SP interfered with
the inhibitory effect of a selected candidate microbicide,
cellulose sulfate, on binding of monoclonal antibodies to
the positively charged V3 loop of HIV-1 IIIB gp120 [41]
(data not shown). This interference was completely abro-
gated by addition of sodium maleate with a negative
charge in the maleate moiety, forming complexes with
polyamines. However, maleate failed to restore the inhib-
itory activity of the polymeric candidate microbicides
against HIV-1 infection to levels observed in the absence
of SP (data not shown). Thus, electrostatic interactions
between SP polyamines and the polyanions tested seem
to provide an incomplete explanation for the suppression
of anti-HIV-1 activities of polymeric candidate microbi-
cides by SP.
The decreased anti-HIV-1 inhibitory activity in vitro of pol-
ymeric candidate microbicides in the presence of SP sug-
gest that these compounds may become less effective in
vivo  in animal models and human clinical trials than
would be expected from macaque efficacy studies using a
semen-free virus challenge [5,6]. This possibility confirms
the need for development of combination microbicides in
which candidate polymers would be supplemented with
anti-HIV-1 compounds remaining fully effective in the
presence of SP, and preferably having a mechanism of
action distinct from that of the polymeric microbicides.
The simplest approach towards this goal, which may also
bypass potential regulatory hurdles resulting from two
active ingredients in a single formulation, is to formulate
the anti-HIV-1 polymers in buffer systems maintaining an
acidic pH (similar to that of a normal vaginal environ-
Dissolution rate of CAP as a function of pH Figure 3
Dissolution rate of CAP as a function of pH. Data are derived from J. Spitael and R. Klinget: Solubility and dissolution rate 
of enteric polymers, Acta Pharmaceutica technologica 1979; S7:163–168 [56].
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ment) even in the presence of semen, and causing inacti-
vation of HIV-1 and other sexually transmitted disease
(STD) pathogens. Such buffering bioadhesive formula-
tions include ACIDFORM [42,43] based on small mole-
CAP solubility in seminal plasma-Aquateric formulation mixtures Figure 4
CAP solubility in seminal plasma-Aquateric formulation mixtures. Increasing volumes of seminal plasma were added 
to one ml of formulation 1 (see Methods section). The pH was measured; the mixtures were centrifuged to pellet most of 
Aquateric and CAP in the supernatant fluids was quantitated [25].
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Table 2: Inactivation of HIV-1 IIIB and BaL by formulated Aquateric (18%) (5 min, 37°C) in the presence of seminal plasma
Seminal Plasma: Formula Ratio % Virus Inactivation
HIV-1 IIIB HIV-1 BaL
Ratio pH Aquateric Pellet Supernatant Aquateric Pellet Supernatant
0.33 3.9 ≥ 99.8 ≥ 99.8 ≥ 99.6 ≥ 99.6
1.0 4.8 ≥ 99.8 ≥ 99.8 ≥ 99.6 ≥ 99.6
3.0 5.43 ≥ 99.8 ≥ 99.8 ≥ 99.6 ≥ 99.6
Virus concentrates of HIV-1 IIIB and Bal, respectively, were diluted 200-fold in seminal plasma and then mixed with Aquateric formulation 1 (see 
Methods section) at volume ratios indicated in the Table. After incubation for 5 min at 37°C, the samples were cooled in ice and centrifuged at 
10,000 rpm for 10 min. The supernatant fluids were neutralized by addition of 1 M Na2HPO4. The pellets containing Aquateric with adsorbed virus 
were resuspended and brought to pH 7.0 by addition of 1 M Na2HPO4. Both the supernatants and the redissolved pellets were mixed with a 
solution of PEG 8000 (final concentration 3%). The resulting pellets were resuspended in DMEM medium and tested for infectivity as described in 
the Methods Section. Virus preparations diluted in seminal fluid but not treated with the Aquateric formulation represented controls.BMC Infectious Diseases 2006, 6:150 http://www.biomedcentral.com/1471-2334/6/150
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cule components, and preferably polymers with built-in
acidic buffering capacity: Carbomer 974P (BufferGel) [44]
and CAP (Fig. 2, 3, 4, 5; Table 1).
To fully appreciate the role of SP ingredients on sexual
transmission of HIV-1, one should consider also the
observations that they appear to cause a decrease of infec-
tious virus titer (see Results; [36,45]). Major contributors
to this phenomenon are probably products resulting from
oxidation of SP polyamines by diamine oxidase [46]
which is also present in this biological fluid [47,48]. The
oxidation is augmented by peroxidase [46]. Peroxidase is
present in a healthy vaginal environment [49,50]. This
suggests that a combination of SP ingredients and a "nor-
mal" vaginal environment might provide a natural
defense system against infection by HIV-1 and other STD
pathogens and might contribute to the low incidence of
HIV-1 transmission per unprotected coital act [8]. In fact,
several viruses and parasites were shown to become inac-
tivated by polyamine oxidation products [51-55]. Efforts
to augment this natural defense mechanism might poten-
tially become part of the microbicide development strat-
egy.
Conclusion
Candidate anti-HIV-1 topical microbicides have been
evaluated for virus inhibitory activities in vitro and efficacy
in animal models mostly without considering the possi-
ble effects semen/seminal plasma may have on the ulti-
mate performance of these compositions. Studies in
macaques challenged vaginally by SIV or SHIV, after
application of anti-HIV-1 compounds, indicated that drug
doses required for protection against infection exceeded
by several orders of magnitude concentrations sufficient
HIV-1 BaL inactivation in seminal plasma-Aquateric formulation mixtures Figure 5
HIV-1 BaL inactivation in seminal plasma-Aquateric formulation mixtures. Increasing volumes of seminal plasma 
were added to aliquots of formulation 2 (see Methods section). After 5 min at 37°C, the samples were cooled in ice, and resid-
ual infectivity was measured. The decrease in extent of virus inactivation reflects both dilutions of the Aquateric formulation by 
seminal plasma and a concomitant pH increase. Samples diluted ≤ 8-fold were cytotoxic due to low pH, and the percentage of 
virus inactivation could not be determined.
Seminal Plasma: Formulation Ratio (v/v)
%
 
H
I
V
-
1
 
B
a
L
I
n
a
c
t
i
v
a
t
i
o
n
0 1 2 4 8
16
32
64
128
256
512
1,024
0
20
40
60
80
100
2
4
6
8
p
H
pH 
% HIV-1 BaL Inactivation BMC Infectious Diseases 2006, 6:150 http://www.biomedcentral.com/1471-2334/6/150
Page 9 of 10
(page number not for citation purposes)
for blocking virus replication in vitro. Since semen/semi-
nal plasma is a vehicle for male to female sexual transmis-
sion of the virus, it is of crucial interest to determine its
potential impact on HIV-1 inhibitory activities of candi-
date products. Such studies are difficult, if not impossible,
in animal models. Therefore, at least a relevant assessment
in in vitro systems is called for. Results presented here indi-
cate that the anti-HIV-1 activity of synthetic polymers, act-
ing as HIV-1 entry inhibitors (carrageenan, cellulose
sulfate, poly(naphthalene sulfonate), polystyrene sul-
fonate and CAP in water soluble form) is greatly dimin-
ished in the presence of SP. The impact of this finding on
performance of these candidate microbicides in vivo
remains unknown. On the other hand, HIV-1 inhibition
by reverse transcriptase inhibitors, UC781 and TMC120
and by zinc finger inhibitors #89 and #247, respectively,
was not affected by SP. Combination of polymeric HIV-1
entry inhibitors with active compounds having a distinct
mechanism of action, and reliance on polymers having
direct virucidal activity and built-in low pH buffering
capacity (contributing to virus inactivation) (CAP in
micronized form; BufferGel) are expected to overcome
potential problems resulting from interference of semen
components with the performance of some microbicides
being considered for, or already in clinical trials.
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